BioNTech SE (22UA) — Cash Flow Quality Index
BioNTech SE (22UA) has a Cash Flow Quality Index of -1.79x as of December 2024. Operating cash flow of €-463.30 Million is below net income of €259.50 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore BioNTech SE (22UA) cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BioNTech SE Cash Flow Quality Index (2020–2023)
Historical Cash Flow Quality Index for BioNTech SE across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check BioNTech SE total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for BioNTech SE (2020–2023)
Year-by-year earnings quality comparison for BioNTech SE. For live market cap and the full company financial profile, see BioNTech SE stock valuation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 5.77x | €5.37 Billion | €930.30 Million | ▲ +301.2% |
| 2022 | 1.44x | €13.58 Billion | €9.43 Billion | ▲ +1564.9% |
| 2021 | 0.09x | €889.70 Million | €10.29 Billion | ▲ +109.7% |
| 2020 | -0.89x | €-13.50 Million | €15.20 Million | — |